MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Revenue
$243,676K
Net Income
-$152,216K
Net Profit Margin
-62.47%
EPS
-$0.78
Unit: Thousand (K) dollars
Revenue Breakdown
Product
Royalty
License And Service
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Total revenues, net
243,676
194,515
155,179*
120,700
Product
10,528
7,732
7,968*
4,028
License Services And Royalty
4,518
2,207
-2,330*
2,535
Total cost of revenues
15,046
9,939
5,638*
6,563
Research and development
149,448
126,636
115,796*
112,874
Selling, general and administrative
186,261
163,896
131,062*
137,621
Restructuring, impairment, and related charges
0
0
6,878*
8,841
Total operating costs and expenses
350,755
300,471
259,373*
265,899
Loss from operations
-107,079
-105,956
-104,194*
-145,199
Interest income
6,659
6,246
4,649*
6,239
Interest expense
13,278
12,942
-20,961*
11,739
Noncash interest expense on deferred royalty obligations
41,345
39,873
15,908*
36,410
Gain on deconsolidation of subsidiaries
-
-
0*
0
Loss on extinguishment of debt
0
0
-75,769*
0
Net loss from equity method investments
-6,435
-18,283
-18,573*
-15,834
Other income, net
5,587
4,253
8,545*
16,461
Total other expense, net
-48,812
-60,599
-76,097*
-41,283
Loss before income taxes
-155,891
-
-180,292*
-186,482
Provision for income taxes
0
-
-397*
-1,545
Net loss
-155,891
-166,555
-179,895*
-184,937
Net loss attributable to redeemable convertible noncontrolling interests and noncontrolling interests
-3,675
-2,512
-1,933*
-2,194
Net loss attributable to common stockholders of bridgebio
-152,216
-164,043
-177,962
-182,743
Basic EPS
-0.78
-0.84
-0.926
-0.95
Diluted EPS
-0.78
-0.84
-0.926
-0.95
Basic Average Shares
195,785,884
194,789,897
192,211,079
191,854,152
Diluted Average Shares
195,785,884
194,789,897
192,211,079
191,854,152
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Net loss
attributable to common...
-$152,216K
(16.32%↑ Y/Y)
Net loss
attributable to redeemable...
-$3,675K
(-98.11%↓ Y/Y)
Net loss
-$155,891K
(15.17%↑ Y/Y)
Loss before income
taxes
-$155,891K
(14.18%↑ Y/Y)
Product
$222,440K
Royalty
$15,432K
License And Service
$5,804K
Loss from operations
-$107,079K
(20.26%↑ Y/Y)
Total other expense,
net
-$48,812K
(-3.02%↓ Y/Y)
Total revenues, net
$243,676K
(120.39%↑ Y/Y)
Interest income
$6,659K
(70.83%↑ Y/Y)
Other income, net
$5,587K
(-14.68%↓ Y/Y)
Total operating costs
and expenses
$350,755K
(43.26%↑ Y/Y)
Noncash interest
expense on deferred...
$41,345K
Interest expense
$13,278K
(-64.72%↓ Y/Y)
Net loss from equity
method investments
-$6,435K
(68.13%↑ Y/Y)
Selling, general and
administrative
$186,261K
(44.22%↑ Y/Y)
Research and development
$149,448K
(34.36%↑ Y/Y)
Total cost of revenues
$15,046K
(311.88%↑ Y/Y)
Product
$10,528K
License Services And
Royalty
$4,518K
Buy us a coffee
BridgeBio Pharma, Inc. (BBIO)
BridgeBio Pharma, Inc. (BBIO)